Mitochondrial dysfunction

Byaibio

Mitochondrial dysfunction is a pathological state in which mitochondria lose normal bioenergetic and quality-control function, making it a shared mechanistic hub across chronic disease trajectories and aging. It is linked to impaired energy production, altered reactive oxygen species signaling, defective biogenesis, mitophagy, and dynamics, and can also amplify downstream inflammatory pathways such as cgas-STING after mitochondrial damage. In the literature, it is implicated in parkinsons disease, atherosclerosis, diabetic kidney disease, myocardial ischemia/reperfusion injury, acetaminophen-induced liver injury, and age-related decline in oocyte aging and skeletal repair. Recent studies also highlight therapeutic strategies that target or restore mitochondrial function, including ginsenosides, hsp90 inhibition, mitochondria targeted delivery, mitochondria targeted hydrogels, and szeto schiller 31, with some approaches aiming to rescue mitochondrial function after myocardial infarction or suppress oxidative and inflammatory cascades. The Key Facts emphasize its role as a shared mechanistic hub for multiple disease trajectories, consistent with its broad classification as a central upstream driver in redox biology and longevity frameworks. Overall, the evidence positions mitochondrial dysfunction as both a disease mechanism and a therapeutic target across neurodegeneration, renal, cardiovascular, hepatic, and aging-related disorders.

Neurodegeneration

  • In Parkinson’s disease, mitochondrial dysfunction is described as a central mechanism driving pathogenesis and may sustain cGAS-STING activation through mitochondrial damage. (PMID:41500413)
  • A 2026 Experimental Neurology review (PMID:41759571) links mitochondrial dysfunction with disrupted neuronal lipid homeostasis in Parkinson’s disease and discusses therapeutic implications.
  • In paclitaxel-treated rats, mitochondrial-related signaling abnormalities were normalized by PNPase inhibition, supporting a role in neural degeneration and mechanical allodynia. (PMID:41948937)
  • In MC-65 cells, 3-deoxyanthocyanidins inhibited β-amyloid toxicity and mitochondrial dysfunction, with molecular dynamics simulations supporting the mechanism. (PMID:41633420)

Kidney and Metabolic Disease

  • In diabetic kidney disease, mitochondrial dysfunction is a key event involving altered reactive oxygen species production, biogenesis, mitophagy, and dynamics. (PMID:41633353)
  • A 2026 Nature Reviews Nephrology paper (PMID:41981250) frames mitochondrial dysfunction as a shared pathological feature of AKI and CKD that drives impaired energy production, oxidative stress, and cell death.
  • The kidney-disease literature also highlights mitochondrial transplantation and other mitochondrial rescue strategies as emerging therapeutic opportunities. (PMID:41981250)

Cardiovascular Disease

  • In myocardial ischemia/reperfusion injury, MK-3903 alleviated mitochondrial impairment in an AMKP-PGC-1α-associated mechanism. (PMID:41671772)
  • A 2026 Bioactive Materials study (PMID:41696142) describes fast mitochondrial rescue by heart-homed nanomedicine to enhance cardiac function after myocardial infarction.
  • Targeting HSP90 mitigated mitochondrial dysfunction and attenuated hypertension-induced atrial fibrillation by suppressing STAT1/CCL8-driven inflammation. (PMID:41720180)
  • In atherosclerosis, mitochondrial dysfunction is linked to oxidative stress, endothelial dysfunction, and inflammatory cascades. (PMID:41668545)

Aging, Reproduction, and Tissue Repair

  • Mitochondrial dysfunction is a major contributor to declining oocyte quality and impaired mitochondrial metabolism during aging. (PMID:41952008)
  • In periosteal mesenchymal stromal/stem cells, mitochondrial G-quadruplex accumulation caused severe mitophagy and cellular senescence, impairing skeletal repair. (PMID:41946679)
  • A 2026 GeroScience review (PMID:41952008) and a 2026 International Journal of Pharmaceutics: X review (PMID:41675221) both position mitochondrial dysfunction as a targetable driver of age-related decline.
  • Dietary ginsenosides were reviewed as longevity interventions that may act in part by modulating mitochondrial dysfunction. (PMID:41945483)

Liver Injury and Therapeutic Delivery

  • In acetaminophen overdose, mitochondrial dysfunction in hepatocytes was identified as the primary cause of liver damage. (PMID:41638489)
  • A 2026 Journal of Controlled Release study (PMID:41638489) reported that mitochondria-targeted coenzyme Q10 nanocarriers, tuned by particle size and lipid composition, alleviated early acetaminophen-induced liver injury.
  • Mitochondria-targeted delivery systems and mitochondria-targeted hydrogels are presented as platforms to alleviate mitochondrial dysfunction across disease settings. (PMID:41691799)
  • The redox-biology framework in a 2026 Nutrients paper (PMID:41901182) places mitochondrial dysfunction upstream of multiple chronic diseases, reinforcing its broad translational relevance.